Dalfampridine is a potassium channel blocker indicated as a treatment to improve walking in adult patients with multiple sclerosis (MS). It is available as extended-release tablets for oral use. MedsAcross supplies Dalfampridine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
AMPYRA is indicated as a treatment to improve walking in adult patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA ® (dalfampridine) is a potassium channel blocker indicated to improve walking in adult patients with multiple sclerosis (MS).
Source: US FDA prescribing information
The mechanism by which dalfampridine exerts its therapeutic effect has not been fully elucidated. Dalfampridine is a broad spectrum potassium channel blocker. In animal studies, dalfampridine has been shown to increase conduction of action potentials in demyelinated axons through inhibition of potassium channels.
Source: US FDA prescribing information
The maximum recommended dosage is 10 mg twice daily (approximately 12 hours apart). There is no evidence of additional benefit with doses greater than 10 mg twice daily. Adverse reactions, including seizures, were more frequent at higher doses. Take with or without food. Administer tablets whole, do not divide, crush, chew, or dissolve. Patients should not take double or extra doses if they miss a dose. Estimated creatinine clearance (CrCl) should be known before initiating treatment with AMPYRA. In patients with mild renal impairment (CrCl 51–80 mL/min), AMPYRA may reach plasma levels associated with a greater risk of seizures, and the potential benefits of AMPYRA should be carefully considered against the risk of seizures in these patients
Source: US FDA prescribing information
The use of AMPYRA is contraindicated in the following conditions: History of seizure Moderate or severe renal impairment (CrCl≤50 mL/min) History of hypersensitivity to AMPYRA or 4-aminopyridine, reactions have included anaphylaxis History of seizure. Moderate or severe renal impairment (CrCl≤50 mL/min). History of hypersensitivity to AMPYRA or 4-aminopyridine
Source: US FDA prescribing information
AMPYRA can cause seizures, the risk of seizures increases with increasing AMPYRA doses, discontinue AMPYRA and do not restart if a seizure occurs. Avoid concomitant use with other forms of 4-aminopyridine (4-AP, fampridine), since the active ingredient is the same. AMPYRA can cause anaphylaxis. Discontinue and do not restart AMPYRA if this occurs
Source: US FDA prescribing information
The following serious adverse reactions are described in more detail elsewhere in the labeling: Seizures Anaphylaxis The most common adverse events (incidence ≥2% and at a rate greater than the placebo rate) for AMPYRA were urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain.
Source: US FDA prescribing information
OCT2 Inhibitors: Concomitant use may cause an increased exposure and potential risk of seizures OCT2 Inhibitors Concurrent treatment with OCT2 inhibitors, such as cimetidine, may cause increased exposure to dalfampridine. Elevated levels of dalfampridine increase the risk of seizures. The potential benefits of taking OCT2 inhibitors concurrently with AMPYRA should be considered against the risk of seizures in these patients.
Source: US FDA prescribing information
Store at 25°C (77°F). Excursions permitted 15°C to 30°C (59°F to 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
2 presentations of Dalfampridine, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Dalfampridine 10 mg extended-release tabletOralGeneric name | — | US FDA | Available on request |
| Ampyra 10 mg extended-release tabletOral | Merz Pharmaceuticals | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 22 January 2010 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Dalfampridine in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 2 presentations of Dalfampridine and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Dalfampridine, including Ampyra.
Yes. The US FDA first approved Dalfampridine on 22 January 2010, according to Drugs@FDA.
No listed presentation of Dalfampridine is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Dalfampridine is classified under ATC code N07XX07 (Dalfampridine).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.